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Figure 4. Macular Pigment Optical Density  
Meso-zeaxanthin Ocular Supplementation Trial in Normals (MOST N) 
 
 
Eithne E. Connolly1, 2, Stephen Beatty1, 2, James Loughman3, John M. Nolan1, 2 
  
1Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland; 2Institute of Vision Research, Whitfield Clinic, Cork Road, Waterford, Ireland; 3Department of 
Optometry, School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland;  
 
 
 
 
 
 
METHODS 
44 healthy subjects were recruited for this study.  22 subjects were randomized 
to consume a formulation containing 10.9 mg of MZ, 5.9 mg of L and 1.2 mg of 
Z (Intervention group [I]), and 22 subjects consumed a placebo containing corn 
starch and rice flour (Placebo group [P]) everyday with a meal over a six month 
study period.  
 
At each study visit (Baseline [V1], 3 months [V2], 6 months [V3]) MPOD (at 
0.25°, 0.5°, 1° and 1.75° degrees eccentricity) was measured using 
customized heterochromatic flicker photometry (cHFP) [Fig. 1].   
 
Blood samples were also collected to analyze serum concentrations of L and 
TZ (total zeaxanthin which includes MZ and Z) by high performance liquid 
chromatography (HPLC) [Fig. 2].  Additional blood samples were collected at 
V1 and V3 and sent to Claymon Biomnis Laboratories, Ireland, for full clinical 
pathology analysis to assess the safety of MZ, L and Z consumption in humans 
[Table 1]. 
 
For MPOD and serum carotenoid data, we conducted repeated measures 
analysis using a general linear model approach. For the clinical pathology 
analysis, we used paired-samples t-tests to test for statistical differences 
between V1 and V3. 
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PURPOSE 
The centre of the macula has a distinct yellow colour attributable to the 
presence of a yellow pigment known as macular pigment (MP).  MP is made 
up of the three lipid-like carotenoids meso-zeaxanthin (MZ), lutein (L) and 
zeaxanthin (Z) (ratio at the macula: 1: 1: 1).1; 2  
 
The MOST N (ISRCTN60816411) study was designed to investigate, in a 
double-blind, randomized placebo controlled fashion, changes in MP optical 
density (MPOD), and serum concentrations of the macular carotenoids in 
response to a supplement containing MZ, L and Z , in normal subjects. 
CONCLUSION 
This double-blind, randomized placebo controlled trial showed significant 
increases in serum concentrations of the macular carotenoids, and MPOD at 
0.25° and 0.5° retinal eccentricity, following supplementation with a formulation 
containing 10.9 mg MZ, 5.9 mg L and 1.2 mg Z. 
 
Of note, MOST N is the first study to investigate, and report on, the safety of 
human consumption of all three macular carotenoids, including MZ.  We conclude 
that the consumption of MZ, L and Z does not produce any medically significant 
changes in the pathology variables tested.  
Email: econnolly@ivr.ie 
Figure 1. cHFP Figure 2. HPLC 
RESULTS 
Serum Carotenoid Analysis 
There was a statistically significant increase in serum concentrations of L and 
TZ* (μmol/L) from baseline at V2 and V3 in the I group (p < 0.005, for all).  As 
expected, there was no statistically significant change from baseline in serum 
concentrations of L and Z in the P group over the study period (p > 0.05, for all) 
[Fig. 3A and B]. 
 
TZ* = total Z concentrations which includes MZ and Z 
Clinical Pathology Analysis 
Statistically significant differences from V1 to V3 were identified in 10 of the 
variables assessed and are highlighted in yellow in Table 1 (some increased and 
some decreased from baseline).  However, and most importantly, all variables at 
each visit (with the exception of LDL, which had a baseline value outside the 
normal reference range) were compared with biological variation data tables at 
http://www.westgard.com/biodatabase1.htm, and were found to be within the 
normal reference range provided. 
 
While LDL also appeared to show a significant difference between visits in the I 
group (p = 0.01), total cholesterol did not show any significant difference between 
visits (p = 0.79), and therefore it is unlikely to be of any medical significance. 
Further investigation is ongoing to confirm this. 
Macular Pigment Optical Density 
There was a statistically significant increase in MPOD at 0.25° and 0.5° retinal 
eccentricity from baseline at V2 and V3 in the I group of the study (p < 0.005, for 
all).   As expected, there was no statistically significant change in MPOD over the 
study period, at any eccentricity measured, in the P group (p > 0.05, for all) [e.g. 
Fig. 4A and B].  
Figure 3. Serum Concentrations of Lutein and Zeaxanthin 
Pathology variable Ref. Range (Unit) V1  V3  p value  V1  V3  p value  
Sodium  135-145 (mmol/L) 139.42 139.26 0.51 139.26 139.26 1.00 
Potassium  3.3-5.3 (mmol/L) 4.16 4.55 0.01 4.26 4.43 0.04 
Chloride  98-107 (mmol/L) 104.05 98.89 0.32 104.05 103.11 0.15 
Urea  2.5-7.7 (mmol/L) 4.72 5.03 0.23 5.31 5.37 0.76 
Creatinine   40-90 (μmol/L) 75.11 76.84 0.42 77.00 74.68 0.15 
Total protein  64-83 (g/L) 72.63 71.05 0.10 71.63 70.05 0.12 
Albumin  37-52 (g/L) 44.47 44.58 0.82 43.53 44.21 0.30 
Globulins  21-36 (g/L) 28.16 26.47 0.11 28.11 26.37 0.07 
Total bilirubin   3.4-21.0 (μmol/L) 8.73 8.21 0.59 8.05 8.77 0.29 
Alanine Aminotransferase   0-55 (IU/L) 24.32 19.42 0.18 22.47 23.16 0.63 
Aspartate Aminotransferase   5-36 (IU/L) 20.37 19.05 0.16 22.16 21.89 0.81 
Alkaline Phosphate  40-150 (IU/L) 78.84 74.63 0.41 79.00 79.95 0.80 
Gamma GT  9-36 (IU/L) 33.84 25.05 0.29 25.16 23.89 0.42 
Cholesterol total  <5.0 (mmol/L) 5.21 5.24 0.79 5.26 4.92 0.02 
Triglycerides  0.60-1.70 (mmol/L) 1.38 1.66 0.13 1.10 1.09 0.93 
HDL  1.00-1.55 (mmol/L) 1.46 1.49 0.63 1.54 1.51 0.46 
Direct LDL  <3.0 (mmol/L) 3.03 3.25 0.01 3.13 2.98 0.23 
Calcium  2.10-2.60 (mmol/L) 2.38 2.35 0.33 2.36 2.36 0.80 
Phosphate  0.80-1.56 (mmol/L) 1.16 1.14 0.63 1.10 1.09 0.82 
Magnesium  0.65-1.10 (mmol/L) 1.00 0.95 0.01 0.98 0.92 0.00 
Uric Acid  155-394 (μmol/L) 263.47 273.47 0.19 274.68 271.74 0.76 
Glucose  3.1-6.1 (mmol/L) 5.31 5.77 0.11 5.03 4.94 0.50 
High Sens. Reactive Protein  <5.0 (mg/L) 4.00 3.31 0.57 1.49 4.18 0.40 
Full Blood Count 
White cell count 3.88-10.49 (10e9/L) 7.07 6.79 0.24 5.97 6.92 0.10 
Red cell count 3.73-5.02 (10e12/L) 4.53 4.58 0.35 4.64 4.58 0.30 
Haemoglobin 11.3-15.2 (g/dL) 14.23 13.91 0.03 14.46 13.85 0.01 
Haematocrit 0.323-0.462 (L/L) 0.40 0.41 0.01 0.40 0.41 0.38 
MCV 83.1-99.1 (fL) 87.93 90.41 0.00 87.06 89.42 0.00 
MCH 28.3-33.9 (pg) 31.42 30.38 0.00 31.15 30.28 0.00 
MCHC 32.1-36.6 (g/dL) 35.75 33.62 0.00 35.78 33.88 0.00 
Platlets 164-382 (10e9/L) 295.47 287.00 0.24 313.28 299.00 0.08 
Diff. White Cell Count 
Neutrophils 1.91-7.16 (10e9/L) 4.39 4.05 0.15 3.44 4.18 0.16 
Lymphocytes 1.01-3.13 (10e9/L) 1.85 1.86 0.92 1.72 1.87 0.04 
Monocytes 0.19-0.68 (10e9/L) 0.42 0.39 0.23 0.36 0.40 0.21 
Eosinophils 0.05-0.51 (10e9/L) 0.25 0.27 0.62 0.24 0.23 0.79 
Basophils 0.02-0.15 (10e9/L) 0.07 0.07 0.71 0.10 0.07 0.10 
L. unstained cells 0.00-0.30 (10e9/L) 0.13 0.13 0.81 0.12 0.16 0.00 
Ref.: Pearson TA et al., Circulation 2003; 107:499-511 : Non Fasting Specimen: Serum/ Plasma Fl. Oxalate/ Whole blood EDTA 
Table 1. Clinical Pathology Variables 
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